Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Award of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 14 January 2019 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces a grant of restricted stock units (‘RSUs’) was made to the Non-Executive Directors on 11 January 2019. This grant is made...
Author: @admin
Holding(s) in Company
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Summit Therapeutics PLCSedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please...
Completion of $25 million subscription
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT
Completion of $25 million subscription
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription to raise $25 million, as approved by shareholders at the Company’s general meeting on 4 January 2019, has...
Holding(s) in Company
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Summit Therapeutics plc 1b. Please indicate if the issuer is a non-UK issuer (please mark...
Completion of $25 million Subscription
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT
Completion of $25 million Subscription
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription to raise $25 million, as approved by shareholders at the Company’s general meeting on 4 January 2019, has...